News Aktuell

Norgine B.V.

15.04.2024 - 16:22

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

Amsterdam (ots/PRNewswire) - Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland ...To the press release of Norgine B.V.

18.05.2023 - 12:00

European study highlights need to improve the quality of conversations about induction of labour (IoL) in clinical settings

Amsterdam (ots/PRNewswire) - - Almost 1 in 2 women (49%) felt the experience of IoL differed from their expectations - The majority of expectant mothers (65%) did not feel fully involved in choosing which method of IoL they prefer - Findings ...To the press release of Norgine B.V.